Compare CAE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAE | LEGN |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 5.9B |
| IPO Year | 2002 | 2020 |
| Metric | CAE | LEGN |
|---|---|---|
| Price | $24.07 | $18.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $33.33 | ★ $61.33 |
| AVG Volume (30 Days) | 723.2K | ★ 1.6M |
| Earning Date | 05-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.97 | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | $35.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.76 | $16.24 |
| 52 Week High | $34.24 | $37.50 |
| Indicator | CAE | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.94 | 38.34 |
| Support Level | $23.01 | $17.81 |
| Resistance Level | $27.11 | $19.36 |
| Average True Range (ATR) | 0.56 | 0.89 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 21.72 | 4.04 |
CAE Inc provides training and aviation services, integrated enterprise solutions, in-service support, and crew-sourcing services. The company operations are managed through two segments: i) Civil Aviation: Provides comprehensive training solutions for flight, cabin, maintenance, ground personnel and air traffic controllers in commercial, business and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training and crew sourcing services, as well as airline operations digital solutions; and ii) Defense and Security which is a world-wide training and simulation provider delivering scalable, platform-independent solutions that enable and enhance force readiness and security. It generates the majority of its revenue from the Civil Aviation segment.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.